Why Do Overseas Registration Timelines for Medical Dressings Get Extended?

Key Summary

For medical dressings undergoing overseas registration, timeline extensions are primarily caused by product classification errors, unclear target market requirements, insufficient technical documentation, and ineffective local agent coordination. If a company treats its product simply as a low-risk dressing and selects a notification-based pathway, but the product claims antibacterial properties, promotes healing, or contacts deep wounds, the actual risk classification may be higher. Regulatory authorities may then require full technical documentation or even clinical data. To determine whether the timeline will be extended, first confirm whether the product falls under medical device regulation in the target country, then determine the risk class and registration pathway.

Companies that already hold NMPA, CE, FDA, or ISO 13485 documentation need to assess item by item which materials can be reused directly and which must be re-validated according to local standards. Performance testing, risk management, clinical evaluation, and labeling must be localized around the target market. In particular, test reports may need to be issued by locally recognized laboratories. Common risks include neglecting the qualifications and responsiveness of the local agent, causing delays in responding to review queries; failing to reserve time for post-market maintenance and renewal; and mixing documentation versions when registering in multiple countries.

Companies should conduct a regulatory assessment early in the project, establish a unified documentation package, define the agent's responsibilities, and develop an overall plan covering registration, changes, renewals, and adverse event reporting. This approach minimizes the commercial loss caused by timeline extensions.

Applicable Scenarios and Core Questions

Medical dressings are a common category in medical device exports, including wound dressings, surgical dressings, and wound care products. When registering overseas, companies often encounter timelines that far exceed expectations. A planned six-month registration may actually take twelve months or more. The problem is usually not the regulatory body's delay, but the company's insufficient understanding of the target market's regulatory rules before project initiation.

Scenarios covered in this article include: companies that have obtained an NMPA registration certificate or filing record in China and wish to export medical dressings to GHWP member countries, Southeast Asian countries, Middle Eastern countries, or Latin American countries; companies with CE or FDA registration experience that intend to reuse their documentation for new markets; and companies that have not yet decided on a target market and are evaluating the feasibility and scheduling of multi-country registrations. Across these scenarios, the causes of timeline extensions have both commonalities and differences.

Companies need to understand that the overseas regulatory classification of medical dressings is not always Class I or low risk. Some countries classify dressings that contact broken skin as moderate risk, requiring technical documentation review. In addition, requirements for local agents, label language, and post-market surveillance vary by country, all of which can affect the overall timeline.

Registration Decision Logic

To determine whether the registration timeline will be extended, first confirm whether the product is within the medical device regulatory scope in the target country. For example, an ordinary dressing used only to cover and absorb exudate may be managed as a general medical product in some countries and not require registration. However, if it claims antibacterial or healing-promoting functions, it may be considered a medical device, and the risk class may increase.

Next, determine the risk class. The risk class of a medical dressing is usually determined by contact duration, contact site, invasiveness, and drug content. Under the EU MDR, most non-invasive wound dressings are Class I, but absorbable dressings for deep wounds may fall into Class IIa or IIb. In other markets, such as Southeast Asia or the Middle East, classification logic may refer to GHTF or local regulations, but the general approach is similar.

The registration pathway determines the timeline. Some countries implement a registration certificate system requiring regulatory review; others use a filing or notification system with shorter timelines. For example, some GHWP member countries require pre-market notification for low-risk products but full review for medium- and high-risk products. Companies should determine the specific registration pathway based on the target market and plan accordingly.

The applicant entity also affects the timeline. Most countries require a local registrant as the certificate holder, so a local agent or authorized representative must be appointed. The agent's qualifications, responsiveness, and communication ability with the regulator directly affect the smoothness of the review process. If the agent is unfamiliar with the product or fails to respond to queries promptly, the timeline will inevitably be extended.

Companies should also assess the reuse value of existing documentation. Can NMPA registration materials, CE technical files, FDA 510(k) submissions, or ISO 13485 certificates be used for the target country? In most cases, portions can be reused, but localization according to target country requirements is necessary. For example, test reports may need to be issued by local laboratories or comply with local standards. If a company assumes all documents can simply be translated and submitted, it is likely to receive deficiency letters during review, leading to extended timelines.

Documentation and Evidence

Core documentation for overseas medical dressing registration includes product technical files, performance verification reports, risk management reports, clinical evaluation or clinical evidence, labeling and instructions for use, and quality management system certificates. The technical file must describe the product design, raw materials, manufacturing process, sterilization method (if applicable), and shelf life.

Performance verification reports must cover the standards required by the target country. For example, absorbency, water vapor transmission rate, bacterial barrier properties, adhesion, and peel strength must be tested according to the applicable standards. If the target country uses ISO standards that differ from domestic standards, additional testing may be required.

Risk management reports are typically prepared based on ISO 14971. Companies must identify risks associated with medical dressings, such as material toxicity, skin irritation, and infection risk, and implement corresponding control measures. The report must align with the intended use defined for the target country and cannot be copied from another market.

Clinical evaluation or clinical evidence is another common cause of timeline extension. For dressings that contact broken skin, some countries may require clinical data. If a company has not conducted clinical studies, a same-device comparison pathway may be used, but sufficient literature or existing data is required. This is often a weak point.

Labels and instructions for use must comply with the target country's language, symbol, and warning requirements. For example, some Middle Eastern countries require Arabic labels, and some Latin American countries require local language. Label content must also align with the registered documentation; if labels are changed after registration, a change application may be necessary.

For the local agent, a power of attorney and proof of the agent's qualifications are required. Post-market maintenance includes adverse event reporting, product change notifications, annual updates, and renewals. These activities must be prepared before registration, not added during the process.

Common Mistakes

• Misidentifying product classification and applying a low-risk pathway, leading to reclassification later and restarting the entire process.
• Relying entirely on NMPA documentation and ignoring differences in test methods required by the target country, resulting in months of additional testing.
• Copying risk management or clinical evaluation content without adjusting for target market demographics and clinical practice.
• Appointing a local agent at the last minute, where the agent is unfamiliar with the product and responds to regulatory inquiries slowly or inaccurately.
• Overlooking label language requirements, forcing redesign and resubmission during review.
• Failing to reserve time for certificate maintenance such as changes, renewals, and adverse event reporting, leading to certificate expiration or product suspension.
• Recompiling documents for each country instead of establishing a unified documentation package, causing version confusion and correction requests.
• Underestimating regulatory review queue times and ignoring holidays and resource constraints.

Enterprise Preparation Checklist

• Clarify the product's intended use, composition, contact time, contact site, and determine its regulatory classification in the target country.
• Research the target country's registration pathway, review timeline, fees, and local agent requirements.
• Inventory existing NMPA, CE, FDA, ISO 13485, and MDSAP documentation and assess the degree of reuse and gaps.
• Develop a technical documentation plan and prepare performance verification, risk management, and clinical evaluation according to target country standards.
• Sign an agreement with the local agent that clearly defines certificate holder responsibilities, change control, and post-market surveillance obligations.
• Prepare label and IFU translations, localization, and review processes in advance.
• Establish a post-market surveillance system covering adverse event reporting, product recall, and annual update plans.
• Design a master file for multi-country registration with unified document numbering and version control to avoid duplicate work.

AIMEILI Regulatory Interpretation and Business Impact

From our case experience, the most common misjudgments are product classification and the degree of documentation reuse. Many companies assume that all medical dressings are low risk and that registration timelines are naturally short, only to be stopped at the classification stage. In reality, once a dressing claims antibacterial properties or is intended for chronic wounds, the risk class may rise and review requirements increase.

The most important step in the early project phase is to conduct a regulatory assessment within two to four weeks after selecting the target market, covering classification, registration pathway, and documentation gap analysis. Effort invested at this stage significantly reduces the probability of later corrections and rework. Do not wait until all documentation is ready before initiating registration; that approach carries a higher time cost.

Regarding documentation, ISO 13485 system certificates, production process descriptions, and raw material information can be reused. However, performance verification reports, clinical evaluations, and label texts must be localized according to the target market. In particular, many countries only accept test reports from local or designated laboratories, so companies must arrange for testing locally in advance.

The local agent is not an optional supporting role. The agent is responsible for communicating with the regulator, receiving the certificate, and handling changes and renewals. If the agent is poorly chosen, control of the certificate may not be in the company's hands, and subsequent changes or renewals may be delayed. Companies should specify the agent's response time and change coordination obligations in the contract.

For multi-country registration, we recommend establishing a “master file plus country-specific supplements” system. The core content remains universal, while the local agent or regulatory team adds country-specific requirements. This approach avoids starting from scratch for each registration and reduces the risk of correction due to version confusion. In AIMEILI's multi-country projects, we consistently use a project management table to track submission dates, inquiry milestones, and expiration dates for each country, which allows early prediction of timeline risks.

Frequently Asked Questions

How long does overseas registration for medical dressings generally take?

The timeline is not fixed and depends on the target country, product classification, and documentation maturity. Low-risk filing products may take several months, while medium- and high-risk review products may take more than a year. A specific estimate should be provided by the local agent or a professional consultancy after a regulatory assessment.

If I already have a CE certificate, can I register in other markets quickly?

A CE certificate and the associated technical file can serve as an important foundation, but they are not directly equivalent. The target country may have different requirements for test standards, label language, and clinical data, which must be supplemented and converted according to local regulations. In addition, the certificate issuer and certificate holder must also comply with local requirements.

How can multi-country registration avoid negative impacts on each other's timelines?

We recommend using a master file system and arranging the registration sequence logically. Prioritize markets with high review requirements or long timelines, and use the review waiting period to complete dossiers for other markets. Key elements are unified document versions, a clear evidence chain, and real-time progress synchronization with each country's agent.